Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits HIV-1 Tat-induced angiogenesis in Kaposi's sarcoma cells.

Kaposi's sarcoma (KS), a neoplasm often associated with iatrogenic and acquired immunosuppression, is characterized by prominent angiogenesis. Angiogenic factors released from KS and host cells and HIV viral products-the protein Tat are reported to be involved in angiogenesis. Mounting evidence further suggests that multiple angiogenic activities of Tat contribute to AIDS-associated Kaposi's sarcoma (AIDS-KS). Herein, we report that sulfated polymannuroguluronate (SPMG), a novel anti-AIDS drug candidate now undergoing phase II clinical trial, significantly eliminated Tat-induced angiogenesis in SLK cells both in vitro and in vivo. SPMG significantly and dose-dependently inhibits proliferation, migration, and tube formation by SLK cells. SPMG also dramatically arrested Tat-driven KDR phosphorylation and blocked the interaction between Tat and integrin beta1, thus inhibiting the phosphorylation of the downstream kinases of FAK, paxillin and MAPKs. In addition, SPMG was noted to block the release of bFGF and VEGF from ECM. All these collectively favor an issue that SPMG functions as a promising therapeutic against Tat-induced angiogenesis and pathologic events relevant to AIDS-KS, which adds novel mechanistic profiling to the anti-AIDS action of SPMG.
AuthorsCong-Xiao Lu, Jing Li, Yong-Xu Sun, Xin Qi, Qing-Juan Wang, Xian-Liang Xin, Mei-Yu Geng
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 74 Issue 9 Pg. 1330-9 (Nov 1 2007) ISSN: 0006-2952 [Print] England
PMID17868650 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-HIV Agents
  • Drug Combinations
  • Gene Products, tat
  • Laminin
  • Polysaccharides
  • Proteoglycans
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • sulfated polymannuroguluronate
  • Fibroblast Growth Factor 2
  • matrigel
  • Collagen
  • Glutathione Transferase
  • Animals
  • Anti-HIV Agents (administration & dosage, pharmacology, therapeutic use)
  • Cell Adhesion (drug effects)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Collagen
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Escherichia coli (genetics)
  • Fibroblast Growth Factor 2 (metabolism)
  • Gene Products, tat (biosynthesis, pharmacology)
  • Glutathione Transferase (metabolism)
  • HIV-1 (metabolism)
  • Humans
  • Laminin
  • Male
  • Mice
  • Neovascularization, Pathologic (drug therapy, metabolism)
  • Polysaccharides (administration & dosage, pharmacology, therapeutic use)
  • Proteoglycans
  • Recombinant Fusion Proteins (biosynthesis, pharmacology)
  • Sarcoma, Kaposi (blood supply, metabolism, pathology)
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: